For example, an anti-HER2 CAR T cells were validated to be effective at targeting HER2+ cancer in preclinical studies and are now being evaluated in a phase I/II clinical trial for treating HER2+ cancers including breast, colorectal, gastric, glioma, lung, ovarian, and pancreatic malignancies (NCT02713984) (42). Here, ERBB2 is linked to central nervous system cancer.